Pfizer Inc 8-K, filed Apr 2, 2020
Pfizer Inc (PFE)
8-K
2020-04-02
For: 2020-04-01
View Original
Added on
April 10, 2026
About this 8-K
Pfizer Inc filed this 8-K on April 2, 2020, reporting on events of April 1, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 1, 2020
(Exact name of registrant as specified in its charter)
(State or other | (Commission File | (I.R.S. Employer |
jurisdiction of | Number) | Identification No.) |
incorporation) | ||
(Zip Code) | ||
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212 ) 733-2323
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act: | ||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Election of Dr. Susan Desmond-Hellmann to the Board of Directors
On April 1, 2020, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Susan Desmond-Hellmann to serve as a member of the Company’s Board, effective immediately. In addition, she was elected to the Governance & Sustainability Committee and the Science and Technology Committee of the Board.
Dr. Desmond-Hellmann has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors.
The press release, dated April 2, 2020, announcing the election of Dr. Desmond-Hellmann is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | Description | |||
Press Release of Pfizer Inc. dated April 2, 2020 | ||||
104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | |||
Exhibit Index
Exhibit Number | Description |
Press Release of Pfizer Inc. dated April 2, 2020 | |
104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PFIZER INC. | ||
Dated: April 2, 2020 | By: | /s/ Margaret M. Madden |
Margaret M. Madden | ||
Senior Vice President and Corporate Secretary | ||
Chief Governance Counsel | ||
Exhibit 99.1 | |||||||
 | |||||||
Contacts | |||||||
Media Relations: | Amy Rose +1 (212) 733-7410 Amy.Rose@Pfizer.com | ||||||
Investor Relations | Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com | ||||||
April 2, 2020
SUSAN DESMOND-HELLMANN ELECTED TO PFIZER’S BOARD OF DIRECTORS
NEW YORK, April 2, 2020— Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the Governance & Sustainability Committee and the Science and Technology Committee of Pfizer’s Board.
Dr. Desmond-Hellmann served as Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 until 2020, where she oversaw the creation of the Gates Medical Research Institute—the world’s first nonprofit biotech organization—as well as the launch of the Economic Mobility and Opportunity investment strategy in the U.S. She remains a Senior Advisor and Board member of the Gates Medical Research Institute. Prior to joining the Bill & Melinda Gates Foundation, she was the first female and ninth overall Chancellor of the University of California, San Francisco (UCSF) from 2009 until 2014, where she still serves as an adjunct professor. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development, from 2005-2009 overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, Dr. Desmond-Hellmann was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute.
1
She served as a Director of Facebook Inc. from 2013 to 2019 and Procter & Gamble from 2010 to 2017.
Dr. Desmond-Hellmann received a B.S. in Pre-Med and an M.D. from the University of Nevada and a M.P.H. from the University of California, Berkeley.
“We are pleased to welcome Dr. Desmond-Hellmann to Pfizer’s Board of Directors,” said Albert Bourla, Pfizer’s Chairman and Chief Executive Officer. “She has made extraordinary contributions throughout her career in medicine, academia, research and global health. With Dr. Desmond-Hellmann's election, we have further bolstered Pfizer’s already strong, diverse Board with additional clinical expertise, scientific insights and respected business leadership.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
2